Gefitinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Gefitinib: From Non-Small Cell Lung Cancer to Gingival Fibromatosis
One-Sentence Summary
Gefitinib is an oral EGFR tyrosine kinase inhibitor, originally used to treat non-small cell lung cancer (NSCLC). The TxGNN model predicts it may be effective for gingival fibromatosis, but this is a model prediction only, with 0 clinical trials and 0 publications supporting this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Non-small cell lung cancer / lung cancer (from the knowledge graph; Singapore label indication text is not available) |
| Predicted New Indication | Gingival fibromatosis |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, gefitinib is a selective EGFR tyrosine kinase inhibitor whose efficacy in EGFR-mutant NSCLC is well established. The literature compiled for other predictions describes it as blocking EGFR signalling, which limits cell proliferation and survival.
A possible link to gingival fibromatosis is EGFR/ERBB signalling in fibroblast proliferation. This is speculative: no trial or publication in the compiled data supports it. Gingival fibromatosis is a benign overgrowth of gum tissue, quite different from a lung malignancy, so the high score (rank 2108 overall) should be treated as a hypothesis to test, not as evidence of benefit.
Other top-ranked predictions show the same weakness. Several are lung neoplasm subtypes that largely overlap with the existing approved use (lung hilum carcinoma, pulmonary sulcus neoplasm). Others, such as the VCP-related myopathy and junctional epidermolysis bullosa, have no evident mechanistic connection, and gefitinib is known to cause skin toxicity.
Clinical Trial Evidence
Currently no related clinical trials registered for gingival fibromatosis.
Literature Evidence
Currently no related literature available for gingival fibromatosis.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16722P | GEFITINIB-TEVA FC TABLET 250MG | Film-coated tablet | Not specified in the data |
| SIN16030P | VEIASU FILM-COATED TABLETS 250 MG | Film-coated tablet | Not specified in the data |
| SIN16055P | INGEFITINIB FILM COATED TABLET 250MG | Film-coated tablet | Not specified in the data |
| SIN16130P | GEFTINAT FILM COATED TABLETS 250 MG | Film-coated tablet | Not specified in the data |
| SIN15984P | HOVID GEFITINIB TABLETS 250 MG | Film-coated tablet | Not specified in the data |
All five registrations are valid single-ingredient oral products.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (EGFR tyrosine kinase inhibitor), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; the literature and knowledge graph point to liver function, respiratory symptoms (interstitial lung disease) and QT interval as relevant |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Contraindication signals (knowledge graph, not label text): liver disease, gallbladder disease, interstitial lung disease, pulmonary fibrosis, and postinflammatory pulmonary fibrosis.
- Safety signals in the literature: published reports describe acute gefitinib-induced pneumonitis or interstitial lung disease (including a fatal case), QT prolongation through hERG channel blockade, a case of recurrent myocardial infarction, and cutaneous toxicities such as acneiform eruption.
- Drug Interactions: 100 interactions were identified; the 18 listed with a severity grade are all Moderate, and two more (calcitriol, glimepiride) have unknown severity. The main groups are:
- Acid-suppressing drugs: famotidine, ranitidine, cimetidine, nizatidine, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole
- CYP-related agents: clarithromycin, miconazole, clotrimazole, aprepitant, dexamethasone
- Others: naltrexone, troglitazone
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (Evidence Level L5), with no trials or literature for gingival fibromatosis. The mechanistic link is speculative. Gefitinib also carries known serious risks (interstitial lung disease, hepatic effects, QT prolongation), which are hard to justify for a benign condition without supporting data.
To proceed, the following is needed:
- Preclinical or case-level evidence that EGFR inhibition affects gingival fibroblast proliferation or fibrosis
- Detailed mechanism of action data
- Singapore package insert warnings, contraindications and approved indication text
- A risk-benefit assessment for a benign condition, including whether topical or local delivery is feasible (the registered products are oral tablets only)
- If a more evidence-supported direction is desired, review the other ranked predictions; the current top ten show no clinical trial support for a new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.